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Background: Potential involvement of the CCR10/CCL28 axis was recently reported in murine models of allergic
asthma. If confirmed, blockade of the CCR10 receptor would represent an alternative to current asthma therapies.
We evaluated the effect of a novel Protein Epitope Mimetic CCR10 antagonist, POL7085, in a murine model of
allergic eosinophilic airway inflammation.
Methods: Mice were sensitized and challenged to ovalbumin. POL7085, a CCR10 antagonist (7.5 and 15 mg/kg),
dexamethasone (1 mg/kg) or vehicle were administered intranasally once daily 1h before each allergen challenge.
On day 21, airway hyperresponsiveness, bronchoalveolar lavage inflammatory cells and Th2 cytokines, and lung
tissue mucus and collagen were measured.
Results: Allergen challenge induced airway hyperresponsiveness in vehicle-treated animals as measured by whole
body barometric plethysmography, and eosinophilia in bronchoalveolar lavage. POL7085 dose-dependently and
significantly decreased airway hyperresponsiveness (34 ± 16 %) and eosinophil numbers in bronchoalveolar lavage
(66 ± 6 %). In addition, the highest dose of POL7085 used significantly inhibited lung IL-4 (85 ± 4 %), IL-5 (87 ± 2 %)
and IL-13 (190 ± 19 %) levels, and lung collagen (43 ± 11 %).
Conclusions: The Protein Epitope Mimetic CCR10 antagonist, POL7085, significantly and dose-dependently decreased
allergen-induced airway hyperresponsiveness and airway inflammation after once daily local treatment. Our data give
strong support for further investigations with CCR10 antagonists in asthmatic disease.
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EosinophiliaBackground
Allergic asthma is a chronic inflammatory disease of the
airways characterized by intermittent episodes of wheez-
ing and coughing. The clinical manifestation of asthma
is caused by an inappropriate response to inhaled aller-
gens, with reversible airway obstruction, airway hyperre-
sponsiveness (AHR), infiltration of inflammatory cells
into the bronchial tissue, mucus metaplasia, allergen-
specific IgE production, and over expression of Th2-
driven cytokines and chemokines such as IL-5, CCL5* Correspondence: nelly.frossard@unistra.fr
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creativecommons.org/publicdomain/zero/1.0/and CCL11. Recently, a possible role for the CCL28/
CCR10 axis in airway disease was postulated [1–4].
CCR10/GPR2 [5, 6] and its two cognate ligands,
CCL27 and CCL28 have been implicated in the regula-
tion of epithelial immunity and related diseases [7, 8].
High expression of CCR10 has been noted in epithelia of
skin, small intestine, colon, salivary glands, mammary
glands, and fetal lung [9–11]. In addition, other cell
types have been reported to express high levels of
CCR10, such as melanocytes, dermal fibroblasts, dermal
microvascular endothelial cells and skin T cells [6, 12],
sub-populations of immune cells such as IgE-secreting B
cells [9, 13] and IgA-secreting plasma cells in mucosal
tissues [7].article distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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CCR10 is non redundant. CCL27 is expressed in skin by
keratinocytes [12] whereas CCL28 is predominantly
expressed by epithelial cells of various mucosal tissues
such as the airway epithelium, salivary glands, mammary
glands, colon, but also by eosinophils and T cells [9–11].
The two chemokines also differ in their selectivity for re-
ceptors, since CCL27 uniquely activates CCR10, whereas
CCL28 activates both CCR10 and CCR3. CCL28 medi-
ates in vitro T and B cell migration through CCR10 [9,
13] whereas it induces migration of human blood eosin-
ophils in a CCR3-dependent fashion [10]. CCL28 is also
thought to play a role in mucosal immunity because of
its intrinsic potent bactericidal activity [11, 14].
The involvement of CCL28 and its receptors CCR3
and CCR10 has been implicated in inflammatory lung
diseases including asthma. CCL28 mRNA expression is
reported in both normal and asthmatic lung tissues [9].
In A549 airway epithelial cells, CCL28 expression is in-
creased upon stimulation with the pro-inflammatory IL-
1β and TNF-α [3] and IL-17A [13]. Furthermore, CCL28
mRNA is substantially higher in biopsy tissue and spu-
tum samples from asthmatics compared to healthy volun-
teers [3], and CCL28 protein concentrations in asthmatic
sputum correlates with IL-17A, CCR10 and CCR3 mRNA
expression [13].
A role for CCL28 and CCR10 in various models of
lung inflammation in mice has also been suggested.
CCL28 expression was increased in the lung of mice
sensitized and challenged with cockroach antigen, and
was associated with increased lung expression of CCR3
but not CCR10, and treatment with CCL28 antiserumFig. 1 Representative structure of Protein Epitope Mimetic (PEM) moleculereduces peribronchial eosinophilia and AHR [2]. By
contrast, in a model of Th2 allergic airway inflamma-
tion in mice sensitized and challenged with ovalbumin
(OVA), inflammation was accompanied both by upreg-
ulation of CCL28 [1], and increased number of CCR10+
cells [1, 15].
Taken together, this evidence suggests relevance for
the CCR10/CCL28 axis in respiratory diseases and, in
particular asthma. We therefore explored the patho-
physiological role of CCR10 in a murine model of allergic
asthma by use of a novel CCR10 antagonist developed
from Protein Epitope Mimetic (PEM) technology (Fig. 1).
PEM are medium sized, fully synthetic cyclic peptide-like
molecules that mimic the two most relevant secondary
structure motifs involved in protein-protein interactions,
ß-hairpins and α-helices [16]. Optimization of a primary
hit family, identified by screening a GPCR-focused subset
of the PEMfinder® library against the human CCR10 re-
ceptor, led to the discovery of POL7085 a potent CCR10
antagonist [17]. We therefore evaluated whether antagon-
izing the CCR10 receptor with POL7085 could reduce the
inflammation-related effects of allergen challenge in a




Nine-week-old male Balb/c mice were purchased from
Janvier Laboratories. Animals were acclimatized under
controlled environmental conditions for at least one week
before use. Animals were maintained under controlled
environmental conditions in conventional husbandry ats
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ity (50 ± 10 %) and 12 h/12 h light–dark cycle (lighting
07:00–19:00). Mice were housed in polycarbonate cages
with four mice per cage (PCT2L12SHT) with bedding
made from spruce wood chips (Safe). The room air was
ventilated at ten air changes per hour according to the
European recommendations. Food (standard diet) and
tap water were available ad libitum. Cages with bedding
were changed weekly. Animal experimentation was
conducted with the approval of the Local Ethics Com-
mittee of the Strasbourg University (Comité Régional
d’Ethique en Matière d’Expérimentation Animale de
Strasbourg).
Synthesis
POL7085 was produced by fluorenylmethoxycarbonyl
solid-phase based synthesis on highly acid labile chloro-
trityl chloride resin (100–200 mesh, Novabiochem, 01-
64-0114) and backbone cyclised [17].
Calcium flux assays
Calcium mobilization assays were performed in Chem-1
cells expressing the human CCR10 receptor (hCCR10;
Millipore) loaded with Fluo-4 or in CHO-K1 cells ex-
pressing the murine CCR10 receptor (mCCR10) in an
apo-aequorin assay (Euroscreen). CCL27 and CCL28
were used at their respective EC80 concentrations (70
nM for CCL27 and 22 nM for CCL28).
Allergen sensitization and challenge
Groups of 6 to 12 Balb/c mice were sensitized i.p. on
days 0 and 7 with 2 mg/kg chicken egg albumin (OVA;
Sigma-Aldrich, A5503) adsorbed on 80 mg/kg alumin-
ium hydroxide (Al(OH)3; Sigma-Aldrich) in saline.
Under i.p. ketamine and xylazine anaesthesia (respect-
ively: Imalgene®, Merial, 50 mg/kg; Rompun®, Bayer,
3.33 mg/kg), sensitized mice were challenged daily on
days 18–21 by intranasal (i.n.) instillation of 400 μg/kg
OVA in saline, or saline alone for controls (1 mL/kg)
[18]. Control animals were sensitized with OVA and
challenged with saline.
Treatment with POL7085 and dexamethasone
POL7085 was used at the doses of 7.5 and 15 mg/kg,
and dexamethasone (DEX) at the dose of 1 mg/kg.
Compounds were solubilised in 10 % (2-hydroxypro-
pyl)-β-cyclodextrin (CDX; Sigma-Aldrich, C0926), and
administered i.n. one hour before each OVA challenge.
Control animals received equivalent volumes (1 mL/kg)
of vehicle.
Measurement of airway responsiveness
Airway responsiveness to aerosolized methacholine (MCh;
Sigma-Aldrich, A2251) was measured in conscious miceon day 22 (24 h after the last OVA challenge) by whole
body barometric plethysmography (Emka Technologies).
Mice were acclimatized in the plethysmograph chamber
for 30 min until a stable baseline was obtained, and then
exposed to aerosolized saline for 30 s as a control. Mice
were then challenged every 20 min with aerosolized MCh
at increasing concentrations (0.05, 0.1, 0.2 and 0.3 M) for
30 s, and the enhanced pause (PenH) was recorded for
5 min and used as an index of airway obstruction [19, 20].
Total and differential cell counts
Bronchoalveolar lavage (BAL) was performed 24 h after
the last OVA challenge as previously described [21].
Mice were anaesthetized i.p. (ketamine 150 mg/kg, xyla-
zine 10 mg/kg). A plastic cannula was inserted in the ex-
posed trachea, and airways were washed with 0.5 mL of
0.9 % NaCl (saline) injected with a 1 mL syringe. This
procedure was performed ten times. The initial concen-
trated supernatant of the two first lavages (2 × 0.5 mL
administered, approx. 0.5 mL recovered) was collected
for cytokine measurements. The remainder of the BALF
was centrifuged (600 g for 5 min, 4 °C), and cell pellets
pooled. After lysis of erythrocytes with distilled water
followed by osmotic re-equilibration and centrifugation,
the cell pellet was suspended in 500 μL of saline and total
cell counted on a haemocytometer chamber (Neubauer,
PRECISS®). Cells were cytocentrifuged at 700 rpm for
10 min (Cytospin 4, Thermo Fischer Scientific), and
stained with Diff-Quick® (Merck) for differential cell
counts performed on at least 400 cells.
Enzyme-Linked Immunosorbent Assays (ELISA)
IL-5, IFN-γ (BD Pharmingen), CCL28 (R&D system)
ELISA kits and Th17 Milliplex® (Millipore) were used ac-
cording to the manufacturer’s instructions. For BALF re-
covered 24 h after the last OVA challenge, IL-5 and
IFN-γ were quantified by ELISA. For lung homogenate,
concentrations of IL-4, IL-5, IL-13, IL-17a and IL-17f
were quantified by Milliplex® in the supernatants ob-
tained after lung tissue was homogenised with an Ultra-
Turax® and centrifuged at 10,000 g for 10 min at 4 °C.
Plasma IgE levels were determined by ELISA. Microti-
ter plates were coated overnight at 4 °C with the capture
antibody, anti-mouse IgE at 2 μg/well in carbonate buf-
fer, pH 9.5 (BD Pharmingen, clone R35-118). OVA-
specific IgE levels were measured using ovalbumin-HRP
(BUF048, Abdserotec) revealed with TMB reagent set
(Pharmingen).
Colorimetric assay of mucus and collagen
Mucus was measured in lung homogenate by a mucus
colorimetric assay: 100 μL samples were mixed with
20 μL acid mucus reagent (0.2 % periodic acid) incu-
bated for 1 h at 37 °C, then 20 μL mucus dye reagent
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added and samples were incubated for a further 30 min
at 37 °C, before optical density measurement at 555 nm.
Collagen in the lung was measured using a collagen
colorimetric assay: 10 μL lung homogenate samples were
added to 200 μL collagen dye reagent (Sirius red
0.017 %, and picric acid 0.8 % in absolute ethanol), vor-
texed for 30 min at 200 rpm at RT, centrifuged at 2400 g
for 20 min at 4 °C. Pellets were solubilised with 200 μL
alkali collagen reagent (absolute ethanol 20 %, sodium
dodecyl sulphate 1.3 %, 2 N sodium hydroxide 12 %),
and optical density measured at 540 nm.
Histological analysis
Lung tissues were fixed in 4 % paraformaldehyde and
paraffin-embedded. 6 μm sections were cut, mounted on
Superfrost glass slides (Fischer Scientific) and stained
with haematoxylin-eosin for light microscopy morpho-
logical analysis or periodic acid-Schiff (PAS) staining to
determine the extent of mucus production. The area of
epithelial cells containing the mucus were measured and
expressed relative to the total bronchus perimeter.
Immunohistochemistry of CCR10
Sections (3 μm) of lung tissue were cut, mounted, placed
in Sequenza® immunostaining with Coverplate™ (Thermo
Scientific Shandon), and antigen retrieval was performed
with proteinase K in Tris-EDTA buffer (pH 8; Fluka) for
35 min at 37 °C. The endogenous enzyme was blocked
with Dual Endogenous Enzyme Block (Dako Cytoma-
tion) and slides were incubated overnight at 4 °C with
the primary antibody 1/1000 (goat anti-mouse CCR10
antibody; Capralogics), followed by 30 min at RT with
the secondary rabbit anti-goat antibody (Vector) and
30 min at RT with extravidin peroxidase (Sigma-Aldrich).
Staining was revealed with a peroxidase substrate (DAB)
and slides counterstained with Fastblue and images were
acquired with a DP72 camera coupled to cellSens® soft-
ware (Olympus).
Real time quantitative PCR (RT-qPCR) analysis
All procedures were performed according to the manu-
facturer’s instructions. Lung tissue was homogenised in
a Fastprep®, and total RNA extracted with Tri-Reagent®
(1 mL/left lung; Euromedex) and purified with mini
RNeasy® Kit (Qiagen). RNA pellets were suspended in
nuclease-free water (DEPC). RNA concentration and
quality were determined in each preparation with a
Nanodrop® spectrophotometer.
Reverse transcription was performed on 10 μg/mL of
total RNA by the High Capacity cDNA Archive kit® (Life
Technologies™) for 10 min at 25 °C and 2 h at 37 °C,
and cDNAs were stored at −80 °C until use. Quantitative
PCR was performed by real-time fluorescent PCR withTaqMan® Gene Expression Assay in 96 well plate format
(Life Technologies™, ABI7000) using TaqMan® Gene Ex-
pression Assay primers (Life Technologies™ for HPRT1
(Mm01545399_m1), CCR10 (Mm01292449_m1), CCL28
(Mm00445039_m1) and CCR3 (Mm00515543_s1). To
analyse the low expression of CCR10, CCL28 and CCR3,
a preamplification was performed with TaqMan® Pre-
Amp Master Mix (Life Technologies™) and TaqMan®
Gene Expression Assay (10 min at 95 °C followed by
14 cycles: 15 s at 95 °C and 4 min at 60 °C). Preamplified
cDNAs were stored at −80 °C until use and diluted 1/20
with 1X TE buffer for use. Reactions were conducted in
a 25 μL final volume containing 12.5 μL TaqMan® Uni-
versal PCR Master Mix (Life Technologies™), 5 μL
cDNA, 1.25 μL TaqMan® Gene Expression assay and
6.25 μL DEPC water for 10 min at 95 °C followed by
40 cycles: 15 s at 95 °C and 1 min at 60 °C. Results are
expressed as cycle thresholds (Ct) that reflect the cycle
number at which the fluorescence curve generated
within a reaction crossed the amplification threshold.
CCR10, CCL28 and CCR3 gene expressions were normal-
ized to the expression of the domestic control gene
HPRT1 (ΔCt = Ctgene−CtHPRT1). Following normalization,
gene expression compared to the mean expression in the
control group (ΔΔCt−ΔCtsample−ΔCtcontrol) and trans-
formed (2ΔΔCt) to obtain the difference in numbers of cop-
ies compared to the control group.
Plasma and tissue measurements of POL7085
Plasma and lung tissue concentrations of POL7085 after
i.n. administration were determined in an independent
experiment. POL7085 was dissolved in CDX and admin-
istered i.n. (12.5 μL per nostril) at 15 mg/kg in BALB/
cBy mice anaesthetised i.p. with ketamine and xylazine.
Under terminal anaesthesia (sodium pentobarbital,
60 mg/kg i.p.), blood was drawn from the vena cava at
5 min, 1 h, 4 h, 8 h and 24 h post-administration, antic-
oagulated with lithium heparin, centrifuged at 500 g for
10 min and the resulting plasma was stored at −20 °C.
Lung lobes were dissected out, weighed and stored fro-
zen at −20 °C until analysis. Concentrations of POL7085
in plasma and lung homogenate supernatants were
determined using a high performance liquid chromatog-
raphy coupled to mass spectrometry detection (UPLC-
4000 Q Trap, Applied Biosystems/MDS Sciex).
Statistical analysis
Data are presented as means ± standard errors of the
mean (SEM). Statistical significance between vehicle and
POL7085 treatment groups or vehicle and DEX treat-
ment groups in the saline- or OVA-challenged mice was
determined using Prism software (GraphPad) by a two-
way ANOVA and Bonferroni post-hoc test for PenH, a
one-way ANOVA followed by Bonferroni post-hoc test























Fig. 2 Lung and plasma concentrations of POL7085 over time following i.n. administration of POL7085 at a dose of 15 mg/kg in mice. Points are
means ± SEM values for n = 3 mice per data point
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by Tukey post-test for biochemical measurements. Data
were considered significantly different when p < 0.05.
Results
Characteristics of POL7085
POL7085 is a potent and selective antagonist of human
and murine CCR10 receptors. POL7085 inhibited cal-
cium flux induced by both CCL27 (IC50 = 42 and 58








































OVA + POL7085 7.5mg/kg
OVA + POL7085 15mg/kg
OVA + DEX 1mg/kg
POL7085 15mg/kg
Fig. 3 Effect of intranasal POL7085 on BAL inflammatory cells 24 h after the l
and lymphocytes recovered in BALF in OVA-sensitized mice challenged with
(n = 6 (saline) or 12 (OVA) per group). ###P≤ 0.001 vs control and **P≤ 0.01, **(IC50 = 45 nM; hCCR10). When tested at concentra-
tions up to 10 μM, the selectivity of POL7085 was more
than 200-fold against a panel of 57 targets, including all
chemokine receptors, GPCRs, cytokine receptors, ion
channels and enzymes [see Additional file 1].
Lung and plasma concentrations of POL7085
Five min after i.n. administration of POL7085 at 15 mg/
kg, lung tissue concentration was 19.9 μg/g, decreasing



































ast challenge. Total numbers of eosinophils, macrophages, neutrophils
OVA or saline. Columns represent group means and bars are SEM values
*P≤ 0.001 vs OVA
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levels (7 ng/mL). These levels are compatible with once
daily treatment with POL7085 with lung exposures
above the IC50 for 24 h (Fig. 2).
In the 21-day model of allergic eosinophilic airway in-
flammation, similar mean concentrations of POL7085
were found in lung (1.6 μg/g) and plasma (1.8 ng/mL)
24 h after the last i.n. administration of POL7085 (not
shown).
Differential cell counts in BAL
Compared to vehicle, POL7085 alone (15 mg/kg) had no
effect on the number of cells recovered in BAL in non-
sensitized animals (Fig. 3). Twenty-four hours after the
last OVA challenge, there was a significant increase of
inflammatory cells in BALF in OVA compared to control
groups (p < 0.001). POL7085 (15 mg/kg) significantly
inhibited eosinophil, neutrophil and lymphocyte recruit-
ment by 65, 64 and 68 %, respectively (p < 0.001) (Fig. 3).



















































































































Fig. 4 Effect of POL7085 on BAL and lung cytokine concentrations and OV
ELISA. c-e Lung tissue IL-5, IL-13 and IL-4 quantified by Milliplex®. f Plasma
means and bars are SEM values for n = 6 or 12 per group (a,b) or n = 3–6 p
***P ≤ 0.001 vs OVAdecreased BAL eosinophil, neutrophil and lymphocyte
numbers (87, 90 and 86 %, respectively; p < 0.001).
Cytokines in BAL and lung homogenate and OVA-specific
IgE levels in plasma
OVA significantly increased the levels of IL-5 in BAL
(p < 0.001); these levels were reduced by POL7085, al-
though not significantly (Fig. 4a). IFN-γ levels were sig-
nificantly decreased by OVA treatment in BAL (p <
0.01) (Fig. 4b), and slightly but non-significantly re-
stored by POL7085.
OVA challenge significantly increased the levels of
IL-4 (p < 0.001), IL-5 (p < 0.001) and IL-13 (p < 0.05) in
lung homogenate (Fig. 4c-e). These levels were dose-
dependently and significantly reduced by POL7085 (p <
0.001, p < 0.05 and p < 0.001, respectively) (Fig. 4c-e).
IL-17a and IL-17f were not detectable (data not
shown). The levels of detectable cytokines were also
significantly decreased by the reference compound
DEX in both BAL and lung homogenate.Control
OVA
OVA + POL7085 7.5mg/kg
OVA + POL7085 15mg/kg







A-specific IgE levels in plasma. a,b BAL IL-5 and IFN-γ quantified by
OVA-specific IgE levels quantified by ELISA. Columns represent group
er group (c-f). #P≤ 0.05, ##P ≤ 0.01, ###P≤ 0.001 vs control; *P≤ 0.05,
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and were challenged with OVA or saline on D18-21.
OVA-specific IgE levels did not increase significantly
24h after the last OVA challenge on D22, and a slight de-
crease, although non significant, was noted with POL7085
or DEX (Fig. 4f).Expression of CCL28 and its receptors in the lung
CCL28 levels were significantly increased by approxi-
mately 25 % in lung (p < 0.05) following OVA challenge.
Treatment with POL7085 reduced lung CCL28 concen-
trations to baseline levels (Fig. 5a, p < 0.05). By contrast,
CCL28 chemokine mRNA levels were not significantly
modified in any group at 24 h after the last OVA chal-
lenge (not shown). CCL28 levels in BAL were highly
variable and inconsistent (not shown). The reference
compound DEX had no effect on CCL28 levels.
Expression of the two CCL28 receptors (CCR10 and
CCR3) mRNA was quantified in the lung as relative to
that of the control group (2ΔΔCt) (Fig. 5b). CCR10
mRNA levels were highly variable in animals sensitized
and challenged with OVA, and it was not possible to de-
termine whether treatment by POL7085 or DEX had any
effect. The 5-fold increase in lung CCR3 mRNA expres-
sion induced by OVA challenge (p < 0.05) was reduced
in mice treated with POL7085 (by 42 %) although reduc-
tion did not reach significance. The reference compound
























































Fig. 5 Effect of POL7085 on lung CCL28 concentration and its receptors m
CCR10 and CCR3 mRNA levels relative to vehicle-treated, saline challenged
means and bars are SEM values for n = 6 or 12 per group (a) or n = 2–6 peRemodelling: mucus and collagen colorimetric assays
Mucus and collagen were measured in lung homoge-
nates. OVA challenge increased both mucus (1.4-fold;
p < 0.05) and collagen (3.7-fold; p < 0.001) in the lung
(Fig. 6a). Treatment with POL7085 had no effect on
mucus, a result confirmed by histology analysis (PAS;
Fig. 6b), but showed significant reduction of collagen
levels (40 %; p < 0.05) (Fig. 6a). The reference com-
pound DEX showed a trend towards reduction of
mucus levels (ns), and a significant reduction of colla-
gen levels (64 %; p < 0.001).Airway responsiveness
Whole body barometric plethysmography was used as
an index of airway obstruction. Twenty-four hours after
the last OVA challenge, inhaled MCh induced a signifi-
cant increase in Penh values as compared to saline-
treated mice (3.7-fold at 0.3 M MCh; p < 0.001).
POL7085 had no effect in saline-challenged animals, but
significantly reduced airway obstruction in OVA-
challenged mice treated with POL7085 at the highest
dose (15 mg/kg; 30 %; p < 0.05; Fig. 7). As expected, the
reference compound DEX also significantly decreased
airway responses to MCh (p < 0.001).Histology
Lungs of mice challenged with saline and treated with ei-
ther vehicle or POL7085 showed no sign of inflammation.Control
OVA
OVA + POL7085 7.5mg/kg
OVA + POL7085 15mg/kg








































RNA. (a) Lung tissue CCL28 levels quantified by ELISA. (b) Lung tissue
control group (2ΔΔCt) quantified by RT-qPCR. Columns represent group
r group (b). #P ≤ 0.05 vs control; *P≤ 0.05 vs OVA










OVA + POL7085 7.5mg/kg
OVA + POL7085 15mg/kg










Fig. 7 Effect of POL7085 on AHR. Airway reactivity to increasing
concentrations of inhaled MCh (0.05-0.3 M) was measured by whole
body plethysmography in unrestrained conscious mice. Symbols
represent group means and bars are SEM values (n = 6 to 12 per
group). ###P ≤ 0.001 vs control and *P ≤ 0.05, ***P ≤ 0.001 vs OVA
OVA + POL7085 7.5mg/kg
OVA + POL7085 15mg/kg
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(a)
(b)
Fig. 6 Effect of POL7085 on lung mucus and collagen levels. a Columns represent group means and bars are SEM values (n = 3–6 per group). #P ≤
0.05, ###P ≤ 0.001 vs control and *P ≤ 0.05, ***P ≤ 0.001 vs OVA. b Representative lung tissue sections (3 μm) showing mucus stain with periodic acid
Schiff, 24 h after the last saline or OVA challenge (magnification x100). Mice received the following treatments: (i) vehicle, saline challenge, (ii) POL7085
15 mg/kg, saline challenge, (iii) vehicle, OVA challenge, (iv) POL7085 7.5 mg/kg, OVA challenge, (v) POL7085 15 mg/kg, OVA challenge, (vi) DEX 1 mg/
kg, OVA challenge
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by marked peribronchial and perivascular inflammatory
cell infiltration (Fig. 8a and b), mostly composed of eo-
sinophils and macrophages with lower numbers of neu-
trophils and lymphocytes. POL7085- (15 mg/kg) and
DEX-treated mice exhibited a substantial reduction of
these cellular infiltrates into the lung (Fig. 8a, iv and v).
Immunohistochemistry (IHC) of CCR10 in the lung
IHC was performed on paraffin-embedded lung sections,
with a goat anti-mouse CCR10 antibody. In control mice
challenged with saline, CCR10 immunoreactivity was
present on airway epithelial and vascular endothelial
cells as well as on smooth muscle of the airways and
pulmonary artery (Fig. 8b and c). Additionally, in OVA-
challenged mice, occasional inflammatory cells, includ-
ing macrophages, were stained positively for CCR10
(Fig. 8b viii). Treatment with POL7085 did not affect the
distribution of CCR10 observed in lung tissue (Fig. 8c iv
and v).
Discussion
Our study reports the effect of the novel selective PEM
CCR10 antagonist POL7085 on a number of inflamma-
tory markers in a murine model of OVA-induced allergic
airway inflammation. Following intranasal administration
to mice, concentrations remained at least 100-fold higher
in lung tissue than in plasma where low concentrations of
(a)
(c)
i ii iii iv v vi






















Fig. 8 Representative lung tissue sections (3 μm) showing peribronchial inflammatory infiltrates 24 h after the last saline or OVA challenge.
a Staining with haematoxylin & eosin (magnification x100). b Immunolabelling of CCR10 in mice challenged with saline (vii) or OVA (viii). CCR10 is
expressed on bronchial and arterial smooth muscle, epithelial and endothelial cells, and occasional inflammatory cells (magnification x400 or
x630). c Immunolabelling of CCR10 on lung sections (magnification x200). Mice received the following treatments: (i) vehicle, saline challenge,
(ii) POL7085 15 mg/kg, saline challenge, (iii) vehicle, OVA challenge, (iv) POL7085 7.5 mg/kg, OVA challenge, (v) POL7085 15 mg/kg, OVA
challenge, (vi) DEX 1 mg/kg, OVA challenge
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duced AHR, bronchial inflammation, and bronchial re-
modelling in terms of collagen production, observations
similar to those reported for CCL28 anti-serum in a virus
challenge model [2].
CCR10 is the receptor for CCL28 chemokine, which is
secreted by bronchial epithelium [9, 10]. In addition,
high levels of CCL28 mRNA have been reported in hu-
man eosinophils [9]. We show here that lung levels of
CCL28 protein were significantly increased after allergen
challenge in OVA-sensitized mice. This finding is in ac-
cordance with reports showing increased CCL28 expres-
sion by airway epithelium and infiltrating leukocytes
following antigen challenge in OVA- or cockroach-
sensitized mice [1, 2]. In contrast, we observed variable
BAL CCL28 mRNA levels, which is consistent with the
report by English and collaborators that in cultured epi-
thelial cells, expression of chemokine mRNA does not
always correlate well with protein production and secre-
tion [1]. Interestingly, we demonstrate that increased
CCL28 lung levels induced by allergen challenge wastotally abolished in mice treated with the CCR10 antag-
onist POL7085, whereas the glucocorticoid DEX had no
effect. However, both agents markedly decreased the
number of eosinophils and lymphocytes recruited to the
airways. We therefore suggest that the contribution of
eosinophils to increased lung CCL28 following allergen
challenge is minor and most CCL28 production is likely
by the airway epithelium, and/or that production of
CCL28 by the infiltrated eosinophils is decreased by the
CCR10 antagonist, and not by DEX. Additional in vitro
experiments on airway epithelia cultured under air-
liquid interface conditions would be required to further
strengthen the dissociation between the inhibitory path-
ways induced by glucocorticoids and CCR10 antagonists
in this asthma model.
Previously it has been reported that CCR10 expression
was evident in both airway epithelium and infiltrating
eosinophils following allergen challenge in a mouse
model of OVA-induced allergic inflammation [1]. Here
we confirm these findings using CCR10 immunolabel-
ling, and in addition demonstrate CCR10 expression on
Daubeuf et al. Respiratory Research  (2015) 16:77 Page 10 of 11endothelial and smooth muscle cells of the airways and
pulmonary vasculature. Furthermore, in mice treated
with the CCR10 antagonist POL7085, like the reference
compound DEX, infiltrating inflammatory cells express-
ing CCR10 were clearly reduced.
Our data also show POL7085 reduced BAL eosinophil
recruitment. This supports the observation that treat-
ment with CCL28 anti-serum decreased airway eosino-
phil numbers [2]. These authors proposed CCL28
induces eosinophil chemotaxis through CCR3, but not
CCR10 [2]. However, we observed that the CCR10 an-
tagonist POL7085 markedly reduced IL-5 levels in lung
homogenate and to a lesser extent in BAL fluid. In con-
trast, John and collaborators reported CCL28 anti-serum
had only a weak inhibitory effect on Th2 cytokines or
eosinophil-attracting chemokine levels in lung homogen-
ate [2]. These contrasting data may be explained by differ-
ences between the models used such as single allergen
challenge used by John and colleagues versus the multiple
allergen challenges in our current study. Our data suggest
CCL28 stimulates Th2 cells to increase IL-5 release and
consequently eosinophil recruitment.
In addition, we report here the significant decrease in
OVA-induced IL-13 production by POL7085. This de-
crease was not related to any decrease in mucus produc-
tion in the airways by POL7085, neither in mucus
staining of airway epithelium, nor in the mucus levels in
whole lung, suggesting mucus secretion is under the de-
pendence of other factors than IL-13 in this model. In
addition, we show that IL-4 was significantly and dose-
dependently decreased after treatment with POL7085,
whereas there were no differences between treatment
groups for OVA-specific IgE, indicating an effect of
CCR10 antagonist on Th2 cells rather than a suppressive
activity on IgE-secreting B cells.
These findings are consistent with the report that
cross-linking of the FcεRI receptors expressed on lung
conventional dendritic cells results in production of
CCL28-mediated recruitment of IL-13-producing T cells
induced by administration of Sendai virus to the lung,
which was reduced by an anti-CCL28 antibody [22].
Viral infections are the most frequent causes of asthma
exacerbations [23, 24] and severe viral infections during
infancy may influence the development of post-viral
atopic diseases via the conventional dendritic cell FcεRI-
CCL28 pathway [25]. We thereby suggest that a study of
the role of a CCR10 antagonist such as POL7085 in the
CCL28-driven lung T cell recruitment during viral infec-
tions in mice would be useful.
During respiratory tract infections, in addition to its
chemokine role in attracting immune cells expressing
CCR10, CCL28 likely provides additional mucosal im-
munity by exerting an antimicrobial effect against patho-
gens [11, 14]. It is therefore important that anytherapeutic agent targeting CCR10 in the airways does
not interfere with this activity, particularly if it were ad-
ministered in combination with immunosuppressive in-
haled corticosteroids. To address this potential risk, we
confirmed that POL7085 did not reduce the antimicro-
bial effect of CCL28 against Pseudomonas aeruginosa
and Candida albicans in viable count assays [see
Additional file 2].
In summary, here we present new evidence supporting
a role for a CCR10 antagonist in allergen-induced bron-
chial inflammation, remodelling and AHR. Combined
with previous findings, our data further implicate CCR10
in airway inflammatory diseases such as asthma. However,
we need to be cautious when translating these data to the
clinical setting, as exemplified by the recent report that
despite strong evidence in preclinical models supporting a
role for CCR3 in asthmatic disease [26], an oral CCR3 an-
tagonist had limited efficacy in a randomized controlled
clinical trial in asthmatics [27]. Nevertheless, our data give
strong support for further investigations with CCR10 an-
tagonists in the asthmatic disease, to allow clinical trials in
particular in poorly controlled asthmatics.Additional files
Additional file 1: POL7085 selectivity profile. Inhibition of
responses of a panel of GPCRs, ion channels and enzymes by
POL7085. Values are % inhibition produced by POL7085 at a single
concentration of (5 or 10 μM), or IC50 where a full concentration-
response was generated.
Additional file 2: Antimicrobial effect of CCL28. Figures show the
effect of CCL28 on viability of Pseudomonas aeruginosa and Candida
albicans, and that POL7085 does not interfere with this activity.Competing interests
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